AI assistant
4D Molecular Therapeutics, Inc. — Director's Dealing 2021
May 20, 2021
33060_dirs_2021-05-19_da1e4656-aa75-4d74-81f1-8ed20f4ce361.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: 4D Molecular Therapeutics Inc. (FDMT)
CIK: 0001650648
Period of Report: 2021-05-17
Reporting Person: SCHAFFER DAVID (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-05-17 | Stock Option (Right to Buy) | $26.89 | A | 22500 | Acquired | 2031-05-16 | Common Stock (22500) | Direct |
Footnotes
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).